Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03078036




Registration number
NCT03078036
Ethics application status
Date submitted
10/02/2017
Date registered
13/03/2017
Date last updated
20/05/2020

Titles & IDs
Public title
International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study
Scientific title
BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study
Secondary ID [1] 0 0
D0816R00012
Universal Trial Number (UTN)
Trial acronym
BREAKOUT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Other interventions - Germline BRCA Test (blood)
Other interventions - FoundationOne Dx Genomic Profile (archival Tumour Specimen)
Other interventions - Follow-up

Observation - Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.


Other interventions: Germline BRCA Test (blood)
If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)

Other interventions: FoundationOne Dx Genomic Profile (archival Tumour Specimen)
Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:
Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.
Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile.

Other interventions: Follow-up
Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.
- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
BRCA Mutational status (BRCA1 mutated and/or BRCA2 mutated or BRCA wild type).
Timepoint [1] 0 0
At one time point at inclusion in the study up to 12 months after the beginning of the study.
Secondary outcome [1] 0 0
Descriptive statistics for treatments administered by line of therapy from 1st line metastatic breast cancer.
Timepoint [1] 0 0
2.5 years (30 months) since the beginning of the study.
Secondary outcome [2] 0 0
Progression free survival by line of therapy
Timepoint [2] 0 0
2.5 years (30 months) since the beginning of the study.
Secondary outcome [3] 0 0
Overall survival by line of therapy
Timepoint [3] 0 0
2.5 years (30 months) since the beginning of the study.

Eligibility
Key inclusion criteria
1. Provision of signed, written and dated informed consent.

2. Adult females (according to the age of majority/adulthood as defined by local
regulations).

3. Histologically or cytologically confirmed HER2-ve breast cancer with evidence of
metastatic disease.

4. Initiated treatment with 1st line systemic cytotoxic chemotherapy (not hormonal
therapy) for metastatic breast cancer in the last 90 days and, at that time, are
considered to have exhausted hormone therapy options (if HR+ve).
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Previous enrolment in this study.

2. Involvement in the planning and/or conduct of this study (applies to both AstraZeneca
staff and/or staff at the study site).

3. Current participation in a clinical study with an investigational oncology product.

4. Previous PARPi therapy, including, but not limited to, participation in a previous
clinical study that included PARPi therapy.

5. Current commencement of PARPi treatment.

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/03/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/05/2019
Sample size
Target
Accrual to date
Final
873
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Research Site - Redcliffe
Recruitment hospital [2] 0 0
Research Site - Kurralta Park
Recruitment hospital [3] 0 0
Research Site - Ballarat
Recruitment postcode(s) [1] 0 0
- Redcliffe
Recruitment postcode(s) [2] 0 0
- Kurralta Park
Recruitment postcode(s) [3] 0 0
- Ballarat
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
United States of America
State/province [5] 0 0
Virginia
Country [6] 0 0
United States of America
State/province [6] 0 0
Washington
Country [7] 0 0
Bulgaria
State/province [7] 0 0
Dobrich
Country [8] 0 0
Bulgaria
State/province [8] 0 0
Ruse
Country [9] 0 0
Bulgaria
State/province [9] 0 0
Sofia
Country [10] 0 0
Canada
State/province [10] 0 0
Ontario
Country [11] 0 0
Canada
State/province [11] 0 0
Quebec
Country [12] 0 0
Germany
State/province [12] 0 0
Tubingen
Country [13] 0 0
Hungary
State/province [13] 0 0
Budapest
Country [14] 0 0
Hungary
State/province [14] 0 0
Szeged
Country [15] 0 0
Hungary
State/province [15] 0 0
Szekszard
Country [16] 0 0
Hungary
State/province [16] 0 0
Szolnok
Country [17] 0 0
Italy
State/province [17] 0 0
Modena
Country [18] 0 0
Italy
State/province [18] 0 0
Varese
Country [19] 0 0
Italy
State/province [19] 0 0
Milano
Country [20] 0 0
Italy
State/province [20] 0 0
Pavia
Country [21] 0 0
Italy
State/province [21] 0 0
Reggio Emilia
Country [22] 0 0
Japan
State/province [22] 0 0
Chiba-Ken
Country [23] 0 0
Japan
State/province [23] 0 0
Ehime-Ken
Country [24] 0 0
Japan
State/province [24] 0 0
Fukuoka-Ken
Country [25] 0 0
Japan
State/province [25] 0 0
Hokkaido
Country [26] 0 0
Japan
State/province [26] 0 0
Miyagi-Ken
Country [27] 0 0
Japan
State/province [27] 0 0
Osaka-Fu
Country [28] 0 0
Japan
State/province [28] 0 0
Tokyo-To
Country [29] 0 0
Korea, Republic of
State/province [29] 0 0
Gyeonggi-do
Country [30] 0 0
Korea, Republic of
State/province [30] 0 0
Busan
Country [31] 0 0
Korea, Republic of
State/province [31] 0 0
Seoul
Country [32] 0 0
Korea, Republic of
State/province [32] 0 0
Ulsan
Country [33] 0 0
Poland
State/province [33] 0 0
Brzozow
Country [34] 0 0
Poland
State/province [34] 0 0
Opole
Country [35] 0 0
Poland
State/province [35] 0 0
Walbrzych
Country [36] 0 0
Poland
State/province [36] 0 0
Warszawa
Country [37] 0 0
Poland
State/province [37] 0 0
Wieliszew
Country [38] 0 0
Poland
State/province [38] 0 0
Wroclaw
Country [39] 0 0
Poland
State/province [39] 0 0
Zory
Country [40] 0 0
Russian Federation
State/province [40] 0 0
Chelyabinsk
Country [41] 0 0
Russian Federation
State/province [41] 0 0
Krasnodar
Country [42] 0 0
Russian Federation
State/province [42] 0 0
Novosibirsk
Country [43] 0 0
Russian Federation
State/province [43] 0 0
Omsk
Country [44] 0 0
Russian Federation
State/province [44] 0 0
Pyatigorsk
Country [45] 0 0
Russian Federation
State/province [45] 0 0
Ryazan
Country [46] 0 0
Russian Federation
State/province [46] 0 0
Tomsk
Country [47] 0 0
Spain
State/province [47] 0 0
Barcelona
Country [48] 0 0
Spain
State/province [48] 0 0
La Coruña
Country [49] 0 0
Spain
State/province [49] 0 0
Madrid
Country [50] 0 0
Spain
State/province [50] 0 0
Burgos
Country [51] 0 0
Spain
State/province [51] 0 0
Girona
Country [52] 0 0
Spain
State/province [52] 0 0
Huelva
Country [53] 0 0
Taiwan
State/province [53] 0 0
Changhua
Country [54] 0 0
Taiwan
State/province [54] 0 0
Kaohsiung
Country [55] 0 0
Taiwan
State/province [55] 0 0
Taichung
Country [56] 0 0
Taiwan
State/province [56] 0 0
Tainan
Country [57] 0 0
Taiwan
State/province [57] 0 0
Taipei
Country [58] 0 0
Turkey
State/province [58] 0 0
Adana
Country [59] 0 0
Turkey
State/province [59] 0 0
Ankara
Country [60] 0 0
Turkey
State/province [60] 0 0
Antalya
Country [61] 0 0
Turkey
State/province [61] 0 0
Diyarbakir
Country [62] 0 0
Turkey
State/province [62] 0 0
Istanbul
Country [63] 0 0
Turkey
State/province [63] 0 0
Izmir
Country [64] 0 0
Turkey
State/province [64] 0 0
Kocaeli
Country [65] 0 0
Turkey
State/province [65] 0 0
Sakarya
Country [66] 0 0
Turkey
State/province [66] 0 0
Samsun
Country [67] 0 0
Turkey
State/province [67] 0 0
Tekirdag
Country [68] 0 0
Turkey
State/province [68] 0 0
Trabzon
Country [69] 0 0
Turkey
State/province [69] 0 0
Van
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Cambridgeshire
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Cornwall
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Derbyshire
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Devon
Country [74] 0 0
United Kingdom
State/province [74] 0 0
East Sussex
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Greater London
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Lancashire
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Staffordshire
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Warwickshire
Country [79] 0 0
United Kingdom
State/province [79] 0 0
West Midlands
Country [80] 0 0
United Kingdom
State/province [80] 0 0
West Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Quintiles; University of Tubingen - Germany
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes
Study BREAKOUT is a prospective cross-sectional cohort study of human epidermal growth factor
receptor 2 negative metastatic breast cancer patients who have started 1st line systemic
cytotoxic chemotherapy. The study will estimate the prevalence of germline breast cancer
susceptibility gene in an otherwise unselected population, describe the treatments
administered and estimate the associated clinical outcomes of overall survival and
progression-free survival amongst mutation carriers within the context of a low poly ADP
ribose polymerase inhibitor treatment setting. Other exploratory analyses may be undertaken
to describe somatic breast cancer susceptibility gene and other homologous recombination
repair gene mutations.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03078036
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03078036